The Impact of Topiramate on Health‐Related Quality of Life Indicators in Chronic Migraine
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background.— Chronic migraine is a disabling primary chronic daily headache disorder that significantly impacts the daily activities of patients with this disorder. To our knowledge, this is the first report of a large, randomized, double‐blind, placebo‐controlled trial that assessed the impact of topiramate on the daily activities, emotional distress, headache‐related disability, and global impression of change in patients with chronic migraine. Objective.— To assess whether topiramate 100 mg/day reduces migraine‐related disability and limitations of daily activities in patients with chronic migraine. Study Design/Methods.— Patients aged ≥18 years with chronic migraine were randomized 1 : 1 ratio to topiramate 100 mg/day or placebo. The double‐blind period lasted 16 weeks. Three patient‐reported outcome measures were administered: Migraine Disability Assessment, Migraine‐Specific Quality of Life Questionnaire (Domains: Role Function Restrictive and Preventive and Emotional Function), and Subject's Global Impression of Change. Investigators completed a Physician's Global Impression of Change for each patient. Subject's Global Impression of Change and Physician's Global Impression of Change were completed one time, at the end of study, and measured on a 7‐point scale (1 = very much improved to 7 = very much worse). The Migraine‐Specific Quality of Life Questionnaire was analyzed using analysis of covariance (last observation carried forward) approach. Results were not adjusted for multiplicity. Results.— A total of 328 patients were randomized (topiramate, n = 165; placebo, n = 163), and 306 patients were included in the intent‐to‐treat population. Mean age was 38.2 years, and a majority of the patients were female (85.3%). Fifty‐six percent of topiramate‐treated patients vs 45% of placebo‐treated patients reported >50% improvement from baseline in Migraine Disability Assessment scores ( P = .074). The Migraine‐Specific Quality of Life Questionnaire analysis demonstrated significant improvements at week 4 in all 3 domains, and at weeks 8 and 16 in both Role Function – Restrictive and Emotional Function domains ( P < .05). Role Function – Preventive approached, but did not reach significance, at week 8 ( P = .053). Seventy‐five percent and 72% of topiramate‐treated patients vs 61% and 59% of placebo‐treated patients reported improvements on the Subject and Physician's Global Impression of Change scales ( P = .025 and P = .037, respectively). Conclusion.— Compared with placebo‐treated patients, topiramate 100 mg/day appears to contribute to reductions in migraine‐related limitations on daily activities and emotional distress beginning as early as week 4 and continuing up to week 16 after treatment. Physician's Global Impression of Change results are very similar with Subject's Global Impression of Change, indicating concordance between the physician's and the subject's assessment of improvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Stewart, W. F., Lipton, R. B., Dowson, A. J., & Sawyer, J. (2001) · Neurology · doi:10.1212/wnl.56.suppl_1.s20 · Cited by 1,210
Validity and Reliability of the Migraine‐Specific Quality of Life Questionnaire (MSQ Version 2.1)
Martin, B. C., Pathak, D. S., Sharfman, M. I., Adelman, J. U., Taylor, F., Kwong, W. J., & Jhingran, P. (2000) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2000.00030.x · Cited by 299
Cited by
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
Chronic migraine: risk factors, mechanisms and treatment
May, A., & Schulte, L. H. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.93 · Cited by 630
American Headache Society (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13456 · Cited by 567
Tassorelli, C., Diener, H.-C., Dodick, D. W., Silberstein, S. D., Lipton, R. B., Ashina, M., Becker, W. J., Ferrari, M. D., Goadsby, P. J., Pozo-Rosich, P., et al. (2018) · Cephalalgia · doi:10.1177/0333102418758283 · Cited by 388
“The Patient Global Impression of Change scale (PGIC) (57) can be used to evaluate subject satisfaction as a secondary endpoint.”
MethodSelf-citationAurora, S. K., Winner, P., Freeman, M. C., Spierings, E. L., Heiring, J. O., DeGryse, R. E., VanDenburgh, A. M., Nolan, M. E., & Turkel, C. C. (2011) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2011.01990.x · Cited by 295
Metadata
- Authors
- Dodick, D. W., Silberstein, S., Saper, J., Freitag, F. G., Cady, R. K., Rapoport, A. M., Mathew, N. T., Hulihan, J., Crivera, C., Rupnow, M. F. T., Mao, L., Finlayson, G., & Greenberg, S. J.
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 47
- Issue
- 10
- Pages
- 1398-1408
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W2137434212
- Cited by
- 83
- References
- 3
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Impact of Topiramate on Health‐Related Quality of Life Indicators in Chronic Migraine. https://app.cochat.ai/papers/10.1111/j.1526-4610.2007.00950.x
- The paper
- Dodick, D. W., Silberstein, S., Saper, J., Freitag, F. G., Cady, R. K., Rapoport, A. M., Mathew, N. T., Hulihan, J., Crivera, C., Rupnow, M. F. T., Mao, L., Finlayson, G., & Greenberg, S. J. (2007). The Impact of Topiramate on Health‐Related Quality of Life Indicators in Chronic Migraine. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2007.00950.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.